Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Hip Fracture Clinical Trial

Official title:

Proprietary Information - Exploratory (Non-Confirmatory) Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00128115
• Other study ID #: 0677-032
• Secondary ID: 2005_028
• Status: Terminated
• Phase: Phase 2
• First received: August 5, 2005
• Last updated: January 19, 2016
• Start date: September 2005
• Est. completion date: August 2007

Study information

• Verified date: January 2016
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 83
• Est. completion date: August 2007
• Est. primary completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Patient has had surgery for a unilateral hip fracture, and is considered to be partially or fully weight bearing after the surgery

• Surgical repair of the fracture has occurred no more than 4 days post hip fracture

• Prior to starting the study medication, the patient is enrolled in a rehabilitation program (as an in-patient or as an out-patient)

• Patient is judged to have been able to ambulate independently at home prior to their hip fracture (able to walk indoors in a familiar setting with little or no aid from another person)

Exclusion Criteria:

• Patient has an unstable medical condition

• Patient has a hip fracture that is due to bone pathology other than osteoporosis (e.g., malignancy, or Paget's Disease), or major trauma (e.g. motor vehicle accident).

• Patient has Type I diabetes

• Patient has Type II diabetes with any of conditions;

1. Patient is currently taking more than one anti-hyperglycemic agent, or is taking a single combination anti-hyperglycemic drug containing more than one anti-hyperglycemic medication

2. Patient is currently receiving insulin. Note: A short-term course of insulin required for glycemic control post hip fracture surgery is not exclusionary

3. Patient has diabetic retinopathy

4. Patient is unwilling or unable to monitor glucose at home

• Patient has been diagnosed with any neuromuscular or neurological disease causing muscle weakness

• Patient has cancer, or had a diagnosis of any malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or adequately treated in situ cervical cancer

• Patient has active carpal tunnel syndrome

• Patient was living in a nursing home prior to the hip fracture (Note: - Patients who were living in an assisted-living facility prior to the hip fracture are eligible for enrollment)

• Patient was permanently wheelchair bound prior to the hip fracture

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hip Fracture
• Hip Fractures

Intervention

Drug:
• MK0677

Locations

Country	Name	City	State
Germany	Msd Sharp & Dohme Gmbh	Haar
Norway	MSD (Norge) AS	Drammen
Spain	Merck Sharp & Dohme De Espana, S.A.E.	Madrid
Sweden	Merck Sharp & Dohme (Sweden) AB	Sollentuna
United Kingdom	Merch Sharp & Dohme Ltd.	Hoddesdon	Hertfordshire

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Countries where clinical trial is conducted

Germany,  Norway,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proprietary Information - Exploratory (Non-Confirmatory) Trial
Secondary	Proprietary Information - Exploratory (Non-Confirmatory) Trial